Genzyme vets raise $37.5M for a new cancer biotech

The stealthy X4 Pharmaceuticals, run by some of former Genzyme execs, has raised $37.5 million to fund its work on new cancer treatments. As Xconomy reports, the company disclosed its Series A fundraise in a regulatory filing but is otherwise staying quiet, saying only that it's at work on oral treatments for difficult-to-treat solid tumors. Genzyme and Lysosomal Therapeutics veteran Paula Ragan services as CEO of X4, and former Genzyme chief Henri Termeer is among the Cambridge, MA, company's founding advisers. More

Suggested Articles

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.

Grid Therapeutics is planning to start trials of its lead cancer immunotherapy GT103 next year after raising $5 million in second-round financing.

The IPO comes as the Flagship startup prepares to test its lead inflammatory disease and anticancer microbial strains in humans.